ASX - By Stock
|
DXB |
Re:
Ann: Dimerix Confirms Phase 3 FSGS Study Design With EMA
|
|
HS2912
|
40 |
11K |
6 |
08/06/21 |
08/06/21 |
ASX - By Stock
|
40
|
11K
|
6
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Dimerix Confirms Phase 3 FSGS Study Design With EMA
|
|
HS2912
|
40 |
11K |
3 |
08/06/21 |
08/06/21 |
ASX - By Stock
|
40
|
11K
|
3
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Dimerix Confirms Phase 3 FSGS Study Design With EMA
|
|
HS2912
|
40 |
11K |
2 |
08/06/21 |
08/06/21 |
ASX - By Stock
|
40
|
11K
|
2
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Dimerix Confirms Phase 3 FSGS Study Design With EMA
|
|
HS2912
|
40 |
11K |
2 |
07/06/21 |
07/06/21 |
ASX - By Stock
|
40
|
11K
|
2
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Dimerix Confirms Phase 3 FSGS Study Design With EMA
|
|
HS2912
|
40 |
11K |
4 |
04/06/21 |
04/06/21 |
ASX - By Stock
|
40
|
11K
|
4
|
|
ASX - By Stock
|
DXB |
Re:
Ann: DMX-200 Remains Eligible for Accelerated Approval
|
|
HS2912
|
22 |
8.0K |
2 |
27/05/21 |
27/05/21 |
ASX - By Stock
|
22
|
8.0K
|
2
|
|
ASX - By Stock
|
DXB |
Re:
Ann: DMX-200 Competitive Position Further Enhanced
|
|
HS2912
|
66 |
16K |
3 |
28/03/21 |
28/03/21 |
ASX - By Stock
|
66
|
16K
|
3
|
|
ASX - By Stock
|
DXB |
Re:
Ann: DMX-200 Competitive Position Further Enhanced
|
|
HS2912
|
66 |
16K |
2 |
26/03/21 |
26/03/21 |
ASX - By Stock
|
66
|
16K
|
2
|
|
ASX - By Stock
|
DXB |
Re:
Ann: DMX-200 Competitive Position Further Enhanced
|
|
HS2912
|
66 |
16K |
5 |
25/03/21 |
25/03/21 |
ASX - By Stock
|
66
|
16K
|
5
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Half Year Report and Update
|
|
HS2912
|
116 |
36K |
11 |
22/02/21 |
22/02/21 |
ASX - By Stock
|
116
|
36K
|
11
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Half Year Report and Update
|
|
HS2912
|
116 |
36K |
9 |
22/02/21 |
22/02/21 |
ASX - By Stock
|
116
|
36K
|
9
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Dimerix Plans for Next Study in Diabetic Kidney Disease
|
|
HS2912
|
169 |
41K |
5 |
29/01/21 |
29/01/21 |
ASX - By Stock
|
169
|
41K
|
5
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Dimerix Plans for Next Study in Diabetic Kidney Disease
|
|
HS2912
|
169 |
41K |
2 |
29/01/21 |
29/01/21 |
ASX - By Stock
|
169
|
41K
|
2
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Dimerix Plans for Next Study in Diabetic Kidney Disease
|
|
HS2912
|
169 |
41K |
0 |
28/01/21 |
28/01/21 |
ASX - By Stock
|
169
|
41K
|
0
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Dimerix Plans for Next Study in Diabetic Kidney Disease
|
|
HS2912
|
169 |
41K |
0 |
28/01/21 |
28/01/21 |
ASX - By Stock
|
169
|
41K
|
0
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Dimerix Plans for Next Study in Diabetic Kidney Disease
|
|
HS2912
|
169 |
41K |
3 |
28/01/21 |
28/01/21 |
ASX - By Stock
|
169
|
41K
|
3
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Dimerix Plans for Next Study in Diabetic Kidney Disease
|
|
HS2912
|
169 |
41K |
0 |
28/01/21 |
28/01/21 |
ASX - By Stock
|
169
|
41K
|
0
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Dimerix Plans for Next Study in Diabetic Kidney Disease
|
|
HS2912
|
169 |
41K |
0 |
28/01/21 |
28/01/21 |
ASX - By Stock
|
169
|
41K
|
0
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Dimerix Plans for Next Study in Diabetic Kidney Disease
|
|
HS2912
|
169 |
41K |
0 |
28/01/21 |
28/01/21 |
ASX - By Stock
|
169
|
41K
|
0
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Dimerix Plans for Next Study in Diabetic Kidney Disease
|
|
HS2912
|
169 |
41K |
0 |
28/01/21 |
28/01/21 |
ASX - By Stock
|
169
|
41K
|
0
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Dimerix Plans for Next Study in Diabetic Kidney Disease
|
|
HS2912
|
169 |
41K |
4 |
28/01/21 |
28/01/21 |
ASX - By Stock
|
169
|
41K
|
4
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Quarterly Appendix 4C and Activities Report
|
|
HS2912
|
18 |
5.3K |
2 |
22/01/21 |
22/01/21 |
ASX - By Stock
|
18
|
5.3K
|
2
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Quarterly Appendix 4C and Activities Report
|
|
HS2912
|
18 |
5.3K |
6 |
22/01/21 |
22/01/21 |
ASX - By Stock
|
18
|
5.3K
|
6
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Quarterly Appendix 4C and Activities Report
|
|
HS2912
|
18 |
5.3K |
9 |
22/01/21 |
22/01/21 |
ASX - By Stock
|
18
|
5.3K
|
9
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Positive Additional Data to Support DMX-200 Development
|
|
HS2912
|
118 |
33K |
0 |
27/10/20 |
27/10/20 |
ASX - By Stock
|
118
|
33K
|
0
|
|
ASX - By Stock
|
DXB |
Re:
Oct 2
|
|
HS2912
|
49 |
16K |
4 |
07/10/20 |
07/10/20 |
ASX - By Stock
|
49
|
16K
|
4
|
|
ASX - By Stock
|
DXB |
Re:
Oct 2
|
|
HS2912
|
49 |
16K |
6 |
07/10/20 |
07/10/20 |
ASX - By Stock
|
49
|
16K
|
6
|
|
ASX - By Stock
|
DXB |
Re:
Ann: CEO's Address to Shareholders
|
|
HS2912
|
94 |
29K |
0 |
02/10/20 |
02/10/20 |
ASX - By Stock
|
94
|
29K
|
0
|
|
ASX - By Stock
|
DXB |
Re:
down but not out
|
|
HS2912
|
12 |
5.8K |
4 |
14/09/20 |
14/09/20 |
ASX - By Stock
|
12
|
5.8K
|
4
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Investor Presentation
|
|
HS2912
|
41 |
20K |
0 |
14/09/20 |
14/09/20 |
ASX - By Stock
|
41
|
20K
|
0
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Positive Top-Line Results in DKD Phase 2 Clinical Study
|
|
HS2912
|
627 |
265K |
3 |
14/09/20 |
14/09/20 |
ASX - By Stock
|
627
|
265K
|
3
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Positive Top-Line Results in DKD Phase 2 Clinical Study
|
|
HS2912
|
627 |
265K |
12 |
14/09/20 |
14/09/20 |
ASX - By Stock
|
627
|
265K
|
12
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Positive Top-Line Results in DKD Phase 2 Clinical Study
|
|
HS2912
|
627 |
265K |
1 |
14/09/20 |
14/09/20 |
ASX - By Stock
|
627
|
265K
|
1
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Positive Top-Line Results in DKD Phase 2 Clinical Study
|
|
HS2912
|
627 |
265K |
1 |
14/09/20 |
14/09/20 |
ASX - By Stock
|
627
|
265K
|
1
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Positive Top-Line Results in DKD Phase 2 Clinical Study
|
|
HS2912
|
627 |
265K |
1 |
14/09/20 |
14/09/20 |
ASX - By Stock
|
627
|
265K
|
1
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Positive Top-Line Results in DKD Phase 2 Clinical Study
|
|
HS2912
|
627 |
265K |
11 |
14/09/20 |
14/09/20 |
ASX - By Stock
|
627
|
265K
|
11
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Positive Top-Line Results in DKD Phase 2 Clinical Study
|
|
HS2912
|
627 |
265K |
6 |
14/09/20 |
14/09/20 |
ASX - By Stock
|
627
|
265K
|
6
|
|
ASX - By Stock
|
DXB |
Re:
DXB - THIS IS IT
|
|
HS2912
|
71 |
37K |
0 |
14/09/20 |
14/09/20 |
ASX - By Stock
|
71
|
37K
|
0
|
|
ASX - By Stock
|
DXB |
Re:
DXB - THIS IS IT
|
|
HS2912
|
71 |
37K |
9 |
14/09/20 |
14/09/20 |
ASX - By Stock
|
71
|
37K
|
9
|
|
ASX - By Stock
|
DXB |
Re:
DXB - THIS IS IT
|
|
HS2912
|
71 |
37K |
6 |
14/09/20 |
14/09/20 |
ASX - By Stock
|
71
|
37K
|
6
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Trading Halt
|
|
HS2912
|
356 |
128K |
1 |
13/09/20 |
13/09/20 |
ASX - By Stock
|
356
|
128K
|
1
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Trading Halt
|
|
HS2912
|
356 |
128K |
1 |
12/09/20 |
12/09/20 |
ASX - By Stock
|
356
|
128K
|
1
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Trading Halt
|
|
HS2912
|
356 |
128K |
0 |
11/09/20 |
11/09/20 |
ASX - By Stock
|
356
|
128K
|
0
|
|
ASX - By Stock
|
DXB |
Civilized General Discussion
|
|
HS2912
|
4 |
1.1K |
1 |
10/09/20 |
10/09/20 |
ASX - By Stock
|
4
|
1.1K
|
1
|
|
ASX - By Stock
|
DXB |
Re:
General Discussion
|
|
HS2912
|
134 |
40K |
1 |
10/09/20 |
10/09/20 |
ASX - By Stock
|
134
|
40K
|
1
|
|
ASX - By Stock
|
DXB |
Re:
General Discussion
|
|
HS2912
|
134 |
40K |
2 |
10/09/20 |
10/09/20 |
ASX - By Stock
|
134
|
40K
|
2
|
|
ASX - By Stock
|
DXB |
Re:
Take a deep breath
|
|
HS2912
|
44 |
17K |
3 |
02/09/20 |
02/09/20 |
ASX - By Stock
|
44
|
17K
|
3
|
|